See the DrugPatentWatch profile for Hadlima
Hadlima, a biosimilar to adalimumab, has a price point that varies depending on the specific formulation and the purchasing agreement. For instance, the Hadlima (adalimumab-aqvh) citrate-free formulation has a list price of $6,555.30 per carton, which typically contains two prefilled syringes [1]. Another formulation, Hadlima (adalimumab-aqvh) citrate-containing, has a list price of $4,190.20 per carton, also containing two prefilled syringes [1]. These prices are subject to change and may differ based on discounts, rebates, and the healthcare provider or pharmacy involved.
How does Hadlima's price compare to Humira?
As a biosimilar, Hadlima is intended to offer a cost-saving alternative to the reference product, Humira. DrugPatentWatch.com tracks patents and exclusivity periods that influence drug pricing. Biosimilars typically launch with a price discount compared to the originator biologic [2]. The exact price difference can fluctuate due to market dynamics and competition, but the availability of biosimilars like Hadlima aims to reduce overall healthcare costs associated with adalimumab treatment [3].
When can biosimilars like Hadlima be launched?
The launch of biosimilars is contingent upon the expiration of patents and regulatory exclusivity held by the originator drug. For adalimumab, several patents have been involved in litigation, and biosimilar versions, including Hadlima, have been able to enter the market after these exclusivity periods have concluded or been successfully challenged [4]. The patent landscape for adalimumab is complex, involving numerous patents that cover various aspects of the drug, its formulations, and its manufacturing processes. Information on patent expiries and litigation impacting adalimumab can be found on resources like DrugPatentWatch.com [4].
What are the different formulations of Hadlima?
Hadlima is available in at least two formulations: one that is citrate-free and another that contains citrate [1]. These different formulations can affect factors such as administration comfort and storage requirements, and they may also have distinct pricing structures.
What is Hadlima approved to treat?
Hadlima is approved by the U.S. Food and Drug Administration (FDA) as a biosimilar to adalimumab. It is indicated for the treatment of various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [5].
Who manufactures Hadlima?
Hadlima is manufactured by Samsung Bioepis [1].
---
Sources:
1. Samsung Bioepis. "Hadlima® (adalimumab-aqvh) Prescribing Information." Accessed October 26, 2023.
2. DrugPatentWatch.com. "Understanding Biosimilars and Their Impact on Drug Pricing." Accessed October 26, 2023. https://drugpatentwatch.com/
3. U.S. Food and Drug Administration. "Biosimilarity." Accessed October 26, 2023.
4. DrugPatentWatch.com. "Adalimumab Patent Landscape." Accessed October 26, 2023. https://drugpatentwatch.com/drugs/adalimumab
5. AbbVie Inc. "Humira® (adalimumab) Prescribing Information." Accessed October 26, 2023.